These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 32267687)

  • 21. Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
    Xie R; Yao Y; Tang P; Chen G; Liu X; Yun F; Cheng C; Wu X; Yuan Q
    Eur J Med Chem; 2017 Jul; 134():1-12. PubMed ID: 28391133
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.
    Franke NE; Niewerth D; Assaraf YG; van Meerloo J; Vojtekova K; van Zantwijk CH; Zweegman S; Chan ET; Kirk CJ; Geerke DP; Schimmer AD; Kaspers GJ; Jansen G; Cloos J
    Leukemia; 2012 Apr; 26(4):757-68. PubMed ID: 21941364
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma.
    Lee SW; Yeon SK; Kim GW; Lee DH; Jeon YH; Yoo J; Kim SY; Kwon SH
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33572814
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy.
    Yang Z; Shen M; Tang M; Zhang W; Cui X; Zhang Z; Pei H; Li Y; Hu M; Bai P; Chen L
    Eur J Med Chem; 2019 Sep; 178():116-130. PubMed ID: 31177073
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo.
    Bono C; Karlin L; Harel S; Mouly E; Labaume S; Galicier L; Apcher S; Sauvageon H; Fermand JP; Bories JC; Arnulf B
    Haematologica; 2012 Jul; 97(7):1101-9. PubMed ID: 22271897
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design, synthesis and docking studies of novel dipeptidyl boronic acid proteasome inhibitors constructed from αα- and αβ-amino acids.
    Shi J; Lei M; Wu W; Feng H; Wang J; Chen S; Zhu Y; Hu S; Liu Z; Jiang C
    Bioorg Med Chem Lett; 2016 Apr; 26(8):1958-62. PubMed ID: 26965867
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5.
    Zhu YX; Tiedemann R; Shi CX; Yin H; Schmidt JE; Bruins LA; Keats JJ; Braggio E; Sereduk C; Mousses S; Stewart AK
    Blood; 2011 Apr; 117(14):3847-57. PubMed ID: 21289309
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors.
    Besse A; Besse L; Kraus M; Mendez-Lopez M; Bader J; Xin BT; de Bruin G; Maurits E; Overkleeft HS; Driessen C
    Cell Chem Biol; 2019 Mar; 26(3):340-351.e3. PubMed ID: 30612952
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel aromatic sulfonyl naphthalene-based boronates as 20S proteasome inhibitors.
    Liu H; Wu J; Ge Y; Li A; Li J; Liu Z; Xu Y; Xu Q; Li Y
    Bioorg Med Chem; 2018 Mar; 26(5):1050-1061. PubMed ID: 29426629
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor.
    Bhatia S; Krieger V; Groll M; Osko JD; Reßing N; Ahlert H; Borkhardt A; Kurz T; Christianson DW; Hauer J; Hansen FK
    J Med Chem; 2018 Nov; 61(22):10299-10309. PubMed ID: 30365892
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma.
    Zang M; Li Z; Liu L; Li F; Li X; Dai Y; Li W; Kuckelkorn U; Doeppner TR; Hermann DM; Zhou W; Qiu L; Jin F
    Cancer Lett; 2015 Oct; 366(2):173-81. PubMed ID: 26116344
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma.
    Gu JJ; Hernandez-Ilizaliturri FJ; Kaufman GP; Czuczman NM; Mavis C; Skitzki JJ; Czuczman MS
    Br J Haematol; 2013 Sep; 162(5):657-69. PubMed ID: 23826755
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of a novel dipeptidyl boronic acid proteasome inhibitor for the treatment of multiple myeloma and triple-negative breast cancer.
    Lei M; Feng H; Bai E; Zhou H; Wang J; Qin Y; Zhang H; Wang X; Liu Z; Hai O; Liu J; Zhu Y
    Org Biomol Chem; 2019 Jan; 17(3):683-691. PubMed ID: 30601533
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of proteasome and class I HDAC inhibitors induces apoptosis of NPC cells through an HDAC6-independent ER stress-induced mechanism.
    Hui KF; Chiang AK
    Int J Cancer; 2014 Dec; 135(12):2950-61. PubMed ID: 24771510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of Novel Epoxyketone-Based Proteasome Inhibitors as a Strategy To Overcome Cancer Resistance to Carfilzomib and Bortezomib.
    Lee MJ; Bhattarai D; Yoo J; Miller Z; Park JE; Lee S; Lee W; Driscoll JJ; Kim KB
    J Med Chem; 2019 May; 62(9):4444-4455. PubMed ID: 30964987
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC.
    Pan T; Dan Y; Guo D; Jiang J; Ran D; Zhang L; Tian B; Yuan J; Yu Y; Gan Z
    Eur J Med Chem; 2021 Nov; 224():113672. PubMed ID: 34237620
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and biological evaluation of curcumin derivatives modified with α-amino boronic acid as proteasome inhibitors.
    Zhang W; Bai H; Han L; Zhang H; Xu B; Cui J; Wang X; Ge Z; Li R
    Bioorg Med Chem Lett; 2018 Aug; 28(14):2459-2464. PubMed ID: 29886021
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib.
    Shabaneh TB; Downey SL; Goddard AL; Screen M; Lucas MM; Eastman A; Kisselev AF
    PLoS One; 2013; 8(2):e56132. PubMed ID: 23460792
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structurally novel highly potent proteasome inhibitors created by the structure-based hybridization of nonpeptidic belactosin derivatives and peptide boronates.
    Kawamura S; Unno Y; Asai A; Arisawa M; Shuto S
    J Med Chem; 2014 Mar; 57(6):2726-35. PubMed ID: 24524217
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of Nek2 by small molecules affects proteasome activity.
    Meng L; Carpenter K; Mollard A; Vankayalapati H; Warner SL; Sharma S; Tricot G; Zhan F; Bearss DJ
    Biomed Res Int; 2014; 2014():273180. PubMed ID: 25313354
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.